News

04-03-2021
New regulatory requirements are currently affecting the In-vitro diagnostic (IVD) industry with the transition from the In-vitro Diagnostic Directive (IVDD) to the In-vitro Diagnostic Regulation (IVDR).

Weiter lesen

05-12-2020
Biotype, together with a clinical cooperation partner, is right now developing a Modaplex panel to detect different genetic aberrations in one single run using synchronized PCR multiplex technologies.

Learn more

 

02-04-2020
Biotype GmbH is commissioned to produce components for the Corona Virus COVID-19 genesig® Real-Time PCR Test by Primerdesign Ltd. A daily capacity of 8,000 to 10,000 tests is planned.

Weiter lesen

 

01-10-2019
Biotype launches 3 new assays on its molecular diagnostic platform ModaplexTM.

Learn more

 

28-06-2019
We are excited to announce that Biotype Diagnostic GmbH and Biotype Innovation GmbH have decided to merge their capabilities to form one strong entity.

Weiter lesen

 

07-02-2019
Biotype expands highly specific CE-IVD portfolio for chimerism monitoring. 56 Mentype® DIPquant assays are now CE-IVD-registered.

Weiter lesen

 

14-12-2018
Within the InfectControl 2020 FINAR BMBF-project the selection for resistances is captured for the first time systematically by specialists coming from the fields of phytopathology, veterinary medicine and infection biology. 

Learn more

 

13-12-2018
SYNLAB Pharma, a subsidiary of SYNLAB Holding Deutschland GmbH announces that it has signed a collaboration agreement with Biotype with the intention to offer a Europe-wide clinical trial service for MSI and POLE/POLD1 mutation detection to indicate if patients harboring from GI cancer or EC would benefit from immune checkpoint inhibitor therapy.

Learn more

 

01-06-2017
Since it was founded in 1999, Biotype Diagnostic GmbH has established an international position developing and marketing outstanding molecular diagnostics systems in the fields of forensics, dermatology and leukaemia. Another mainstay is producing complex testing systems commissioned by global players such as QIAGEN GmbH. Now, Biotype is extending its OEM business and exceptional skills in developing and producing made-to-order multiplex PCR assays in new fields.

Read more

 

14-03-2017
The new assays DigitalScreen/DigitalQuant of the Biotype Diagnostic GmbH ensure a robust and highly sensitive evaluation of disease progression after stem cell transplantation based on the innovative digital PCR technology.

Read more

 

23-02-2016
Quantitative Strategy for Chimerism Monitoring – new method provides significant increase in sensitivity by factor 20 which translates into massive time advantage

Read more
 

 

18-01-2016
50 molecular markers combined with highest sensitivity result in a dramatic improvement of chimerism monitoring

Read more